Annexon Inc - Asset Resilience Ratio
Annexon Inc (ANNX) has an Asset Resilience Ratio of 18.95% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See how liquid is Annexon Inc's working capital to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2020–2025)
This chart shows how Annexon Inc's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see Annexon Inc total assets.
Liquid Assets Composition Over Time
This chart breaks down Annexon Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read ANNX liabilities breakdown for a breakdown of total debt and financial obligations.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $49.82 Million | 18.95% |
| Total Liquid Assets | $49.82 Million | 18.95% |
Asset Resilience Insights
- Good Liquidity Position: Annexon Inc maintains a healthy 18.95% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company has significant short-term investments, indicating active treasury management.
Annexon Inc Industry Peers by Asset Resilience Ratio
Compare Annexon Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
ALK-Abelló A/S
CO:ALK-B |
Biotechnology | 0.98% |
|
Mirum Pharmaceuticals Inc
NASDAQ:MIRM |
Biotechnology | 6.89% |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278 |
Biotechnology | 4.69% |
|
BB Biotech AG
SW:BION |
Biotechnology | 92.97% |
|
Soleno Therapeutics Inc
NASDAQ:SLNO |
Biotechnology | 20.15% |
|
Nanobiotix
NASDAQ:NBTX |
Biotechnology | 4.71% |
|
Wuhan Keqian Biology Co Ltd
SHG:688526 |
Biotechnology | 19.42% |
|
Beijing Konruns Pharmaceutical Co Ltd
SHG:603590 |
Biotechnology | 10.55% |
Annual Asset Resilience Ratio for Annexon Inc (2020–2025)
The table below shows the annual Asset Resilience Ratio data for Annexon Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 27.49% | $76.29 Million | $277.57 Million | -47.50pp |
| 2024-12-31 | 74.99% | $262.52 Million | $350.07 Million | +63.36pp |
| 2023-12-31 | 11.63% | $34.61 Million | $297.67 Million | -24.38pp |
| 2022-12-31 | 36.00% | $102.64 Million | $285.10 Million | -22.48pp |
| 2021-12-31 | 58.48% | $167.87 Million | $287.04 Million | +35.27pp |
| 2020-12-31 | 23.22% | $82.64 Million | $355.95 Million | -- |
About Annexon Inc
Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. The company provides Tanruprubart, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase… Read more